Agree, and as you say the acquirer must be European, otherwise why would Tyler Blok be there in Munich? The only clinker there for me there is that we know Merck (US, not German) is aware of the data from that MD Anderson mTNBC preclinical trial, and we recently had Dr Tripathy (very much an MD Anderson guy) join the SAB. Setting that aside, for me the number one candidates to acquire CytoDyn are AstraZeneca and Roche...Both have a PD-L1 blocker, and Roche has shown interest in CCR TME modulating drugs. Whichever, it's an exciting time for all of us longs!